Craven House Capital PLC
10 September 2024
Certain information contained
within this Announcement is deemed by the Company to constitute
inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 ("MAR") as applied in the United Kingdom. Upon
publication of this Announcement, this information is now
considered to be in the public domain.
Craven House Capital
plc
("Craven House" or the
"Company")
Investee company update: RoseMonkey
Ltd
The Company confirms that RoseMonkey Ltd (a
company in which Craven has a 24.4% shareholding in) has notified
it that it has sold certain IP rights and participated in a
financing transaction with Quiapeg Pharma AB
("QuiaPeg").
Following completion of the transactions,
RoseMonkey was awarded 1,416,007,811 shares in QuiaPeg. RoseMonkey
elected to distribute a proportionate amount of those shares to
Craven House.
Craven House has therefore received 345,505,096
shares representing 23.2% of QuiaPeg and a market value of
approximately $758,792 as at September 9th,
2024.
QuiaPeg is a drug development
company based on a patented drug delivery platform, Uni-Qleaver®,
and the company develops improved and patentable forms of drugs
under development or already approved by regulatory authorities.
QuiaPEG's shares are admitted to trading on Nasdaq First North
Growth Market.
Craven House remains a 24.4% shareholder in
RoseMonkey Ltd.
For further information please
contact:
About
Craven House Capital:
The Company's Investing Policy is primarily to
invest in or acquire a portfolio of companies, partnerships, joint
ventures, businesses or other assets participating in the
e-Commerce sector.
